This announcement is a separate document:
大塚ホールディングス：大塚製薬は、成人の免疫グロブリンA腎症の治療薬としてのシベプレンリマブの第3相試験の肯定的な中間結果を発表しました
Otsuka Holdings: Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated